PsiThera News and Activities

Acquisition, funding and merger involving PsiThera.

• Psivant Therapeutics has changed its company name to PsiThera (posted on January 9 2026).
• PsiThera has just announced a $48 Million fundraising (posted on January 9 2026).

View the org chart displaying its 17 main executives

Most searched biographies at PsiThera

• Eric Shaff, Chief Executive Officer
• James Edwards, Director
• Alex Gasner, Chairman of the Board

Create your alert
to follow the executive moves at PsiThera.

PsiThera has 2,413 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Ollin Biosciences has just announced a $330 Million fundraising (posted on June 24 2026).
• RQ Biotechnology has just announced a $86 Million fundraising (posted on June 24 2026).
• Boundless Bio has filed its IPO. Its stock ticker will be AATD. (posted on June 23 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by PsiThera

• SK Biopharmaceuticals
• SK Biopharmaceuticals
• Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs | Proteovant Therapeutics
• Roivant Unveils Targeted Protein Degradation Platform
• Blueprint Medicines and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degrader Therapies

Social media about PsiThera

• PsiThera on Wikipedia, Google News & Yahoo Finance
• PsiThera on LinkedIn, X (Twitter) & YouTube